Cline Darren S 4
4 · Xenon Pharmaceuticals Inc. · Filed Jun 24, 2025
Insider Transaction Report
Form 4
Cline Darren S
Chief Commercial Officer
Transactions
- Award
Share Option (Right to Buy)
2025-06-23+185,800→ 185,800 totalExercise: $31.49Exp: 2035-06-22→ Common Shares (185,800 underlying)
Footnotes (1)
- [F1]Vesting 25% on June 23, 2026, and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month.